Serotonin receptor subtype with anxiolytic effects, particularly in amygdala and hippocampus, and the primary target mediating SSRI therapeutic benefit. As an autoreceptor on serotonin neurons, it temporarily reduces serotonin release until desensitization occurs; buspirone acts directly on this receptor.

Serotonin receptor subtype whose activation produces anxiety-increasing effects in amygdala and BNST. Early SSRI-induced activation of 5-HT2C receptors (before 5-HT1A desensitization) causes initial treatment worsening; over weeks, these receptors desensitize, allowing anti-anxiety effects to emerge.

Serotonin-transporter-linked polymorphic region. A genetic variant in the SERT gene promoter once thought to predict depression and anxiety risk. The short allele was widely studied but large replication efforts (including Culverhouse et al., 2018) found no reliable main effect. Now considered a cautionary tale in psychiatric genetics.

A plan under Section 504 of the Rehabilitation Act providing accommodations (but not specialized instruction) for students with disabilities.

American Academy of Child and Adolescent Psychiatry. Publishes practice parameters for assessment and treatment of childhood psychiatric disorders.

American Academy of Pediatrics. Publishes clinical practice guidelines for psychiatric and developmental disorders in children.

Adolescent Brain Cognitive Development Study. An ongoing longitudinal cohort of roughly 12,000 U.S. youth, providing the most granular developmental neuroimaging data available for studying how the brain develops through adolescence.

Brief staring spells caused by abnormal brain electrical activity. Can mimic inattention.

A change in how instruction or testing is delivered that removes barriers without altering content or expectations. Contrast with modification, which changes what the student is expected to learn.

Adverse Childhood Experience. An index of childhood trauma exposure linked to increased risk of psychiatric and medical conditions.

Acceptance and Commitment Therapy; transdiagnostic psychotherapy emphasizing values clarification, acceptance of unwanted internal experiences (thoughts, sensations, emotions), and committed action toward meaningful life goals. Shows efficacy across anxiety disorders as an alternative to trauma-focused or disorder-specific CBT.

Americans with Disabilities Act. Federal civil rights law prohibiting discrimination against individuals with disabilities.

The degree to which a patient follows prescribed treatment recommendations.

Autism Diagnostic Interview-Revised. A structured caregiver interview for autism diagnosis.

Anxiety Disorders Interview Schedule for adults; definitive diagnostic gold standard for specialty settings. Uses branching logic to establish diagnoses with 0-8 dimensional severity scale across anxiety, mood, OCD, somatic, and substance use disorders.

Anxiety Disorders Interview Schedule for Children; semi-structured diagnostic interview with parallel child and parent versions. Yields clinical severity ratings on 0-8 scale with 4 or above indicating full DSM criteria met with clinically significant impairment.

Autism Diagnostic Observation Schedule, 2nd Edition. A standardized assessment tool for diagnosing autism spectrum disorder.

Melatonin receptor agonist and 5-HT2C antagonist approved in Europe for depression with evidence of anxiolytic properties. Not FDA-approved in United States; available through international prescribing. Minimal sexual dysfunction and discontinuation syndrome compared to SSRIs.

A substance that binds to a receptor and activates it, mimicking the natural signaling molecule.

Anxiety disorder characterized by intense fear and avoidance of places or situations where escape is difficult or help is unavailable, often involving public transportation, open spaces, enclosed spaces, or being alone outside the home.

An intensely distressing sense of inner restlessness and inability to sit still. A potential side effect of some psychiatric medications.

A medication that activates alpha-2 adrenergic receptors, reducing sympathetic nervous system activity.

Short-acting benzodiazepine (Schedule IV) used for acute anxiety and panic attacks. Rapid onset (15-30 minutes), relatively short duration (6-12 hours), prone to rebound anxiety and dependence; use restricted to short-term crisis intervention.

Tertiary amine tricyclic antidepressant with broad receptor activity (serotonin, norepinephrine, histamine, acetylcholine). Used primarily for chronic pain and migraine prophylaxis rather than anxiety due to its side effect burden and overdose lethality compared to SSRIs.

A brain structure involved in processing fear, emotional memory, and threat detection. Also plays a role in reward processing and social cognition.

The inability to experience pleasure from activities that are normally enjoyable.

A substance that binds to a receptor and blocks its activation.

Changing environmental triggers before a behavior occurs to prevent problem behaviors.

A brain region involved in error detection, conflict monitoring, and emotional regulation.

A brain network relationship where one network's activation reliably coincides with another network's deactivation. The default mode network and task-positive network are anti-correlated: when one turns on, the other turns off. In ADHD, this switching is unreliable.

Anxiety occurring in anticipation of feared situation or event before threat actually occurs. Characteristic of panic disorder and social anxiety; can become as impairing as phobic response itself.

A state of excessive worry, apprehension, or fear that is disproportionate to the situation. When persistent and impairing, it constitutes an anxiety disorder. Anxiety is among the most common psychiatric comorbidities in ADHD.

DSM-5 specifier indicating presence of at least two anxiety symptoms (worry, difficulty concentrating, etc.) during mood episode, modifying major depressive or bipolar disorder diagnoses to recognize dimensional anxiety-mood overlap.

American Psychiatric Association clinical practice guidelines (distinct from APA = American Psychological Association) providing evidence-based recommendations for diagnosis and treatment of psychiatric disorders including anxiety disorders. Updated periodically to reflect current evidence.

Structured relaxation technique combining progressive muscle relaxation training with application of relaxation cues (brief tension-release cycles) to produce rapid anxiety reduction during anxiety-provoking situations. Guideline-supported standalone intervention for panic and GAD, though component meta-analyses suggest caution using during exposure.

Specialized exposure technique for blood-injection-injury (BII) phobia that leverages tension-release cycles to prevent the vasovagal fainting response characteristic of this phobia. Patient tenses large muscle groups for 10-15 seconds, releases, repeats; combined with in vivo exposure to blood/injury stimuli.

Abbreviated Penn State Worry Questionnaire; brief version of PSWQ measuring pathological worry intensity and uncontrollability. 8-item format; more practical than 16-item PSWQ for routine assessment; correlates strongly with full version.

Extended-release methylphenidate using a multi-particulate beaded system with a 40:60 immediate-to-delayed release ratio.

An atypical antipsychotic with dopamine partial agonist activity, used as adjunctive treatment for depression and irritability across diagnostic categories.

Autism Spectrum Disorder. A neurodevelopmental disorder characterized by differences in social communication and restricted/repetitive behaviors.

The co-occurrence of Autism Spectrum Disorder with another condition such as ADHD. The DSM-5 removed the previous prohibition on dual ASD-ADHD diagnosis, recognizing that 30-50% of individuals with ASD independently meet criteria for ADHD with distinct impairment from each disorder.

Anxiety Sensitivity Index-3; 18-item self-report measuring fear of anxiety symptoms themselves (anxiety about racing heart, fear of physical sensations), a transdiagnostic vulnerability factor. Total score 0-72; correlates strongly with panic disorder and specific phobia severity.

Any device or software that helps a person with a disability perform tasks they would otherwise find difficult.

Caribbean and Latin American cultural syndrome of acute anxiety/panic episodes characterized by uncontrollable shouting, crying, trembling, and sometimes aggressive or self-injurious behavior. Culturally syntonic expression of distress; symptoms overlap with panic disorder but include social/family context and post-episode fatigue.

Adding a second medication or intervention to an existing treatment to enhance the overall response.

A neurodevelopmental condition characterized by differences in social communication and restricted or repetitive behaviors. Frequently co-occurs with ADHD; DSM-5 permits dual diagnosis. Abbreviated ASD.

Beck Anxiety Inventory; 21-item proprietary scale emphasizing somatic and autonomic symptoms. Total score 0-63; correlates strongly with panic disorder severity but systematically underestimates cognitive worry in GAD.

A group of subcortical nuclei (including the caudate, putamen, and globus pallidus) involved in motor control, habit formation, and reward processing. Structural and functional differences in basal ganglia circuits are consistently observed in ADHD neuroimaging research.

The prevalence of a condition in the population being tested, which directly affects the meaning of test results.

Brain-Derived Neurotrophic Factor. A protein essential for the growth and survival of neurons, involved in neuroplasticity and learning.

A therapeutic technique that systematically increases engagement in meaningful activities to counteract patterns of avoidance and withdrawal.

Structured test of anxious predictions designed to gather evidence disconfirming catastrophic thoughts. Patient predicts disaster will occur, engages in feared behavior, and observes what actually happens.

The brain's ability to suppress an automatic response and pause before acting, allowing deliberate decision-making. A foundational concept in Barkley's model of ADHD, where deficient behavioral inhibition is considered the core deficit.

An evidence-based psychosocial intervention that teaches parents specific behavior management techniques including positive reinforcement, structured routines, and consistent consequences. Recommended as first-line treatment for preschoolers with ADHD.

A class of medications that enhance GABA activity to produce sedative, anxiolytic, and muscle-relaxant effects. Generally avoided in ADHD populations due to cognitive dulling, dependence risk, and potential for misuse.

The proportion of an administered drug that reaches the bloodstream in active form.

Psychophysiological technique where patient receives real-time feedback on autonomic nervous system functions (heart rate, muscle tension, skin conductance) to learn voluntary control. Can supplement exposure therapy by helping patients recognize and modulate anxiety responses.

Behavior Intervention Plan. A plan based on an FBA that outlines strategies for addressing problem behaviors in school settings.

The FDA's strongest safety warning on a medication label (formally called a Boxed Warning), indicating serious or life-threatening risks.

Body Mass Index. A measure of body weight relative to height, widely used in clinical assessment and growth monitoring.

Brain structure adjacent to amygdala that generates slow, sustained anxiety in response to unpredictable or diffuse threats. Functionally separable from amygdala, which produces acute phasic fear; forms extended amygdala with amygdala.

Behavioral Parent Training. An evidence-based intervention teaching parents specific behavioral management strategies for children with behavioral disorders.

Behavior Rating Inventory of Executive Function, 2nd Edition. A rating scale measuring executive function abilities in daily life.

A rating scale that screens across many types of problems rather than focusing on one disorder.

An antidepressant (Wellbutrin) sometimes used off-label for attention and mood disorders. A norepinephrine-dopamine reuptake inhibitor (NDRI).

Azapirone anxiolytic working as 5-HT1A partial agonist; used for GAD and as augmentation to SSRIs. Slower onset than benzodiazepines (2-4 weeks) but lacks abuse liability, sedation, and discontinuation syndrome.

Adenosine receptor antagonist and the most widely consumed psychoactive substance. In anxiety contexts, caffeine can provoke or exacerbate panic attacks and generalized anxiety symptoms through sympathetic activation; doses above 200-300 mg/day are clinically relevant.

Child/Adolescent Anxiety Multimodal Study. Landmark RCT (N=488, ages 7-17) comparing sertraline, CBT, combination, and placebo for childhood anxiety disorders. Combination treatment showed 81% response rate versus 60% for CBT alone, 55% for sertraline alone, and 24% for placebo.

Canadian Network for Mood and Anxiety Treatments clinical practice guidelines providing evidence-based recommendations for pharmacotherapy of anxiety disorders. Regularly updated; emphasize stepped-care approaches and measurement-based care.

Clinician-Administered PTSD Scale, Fifth Edition; 30-item gold-standard diagnostic interview for PTSD measuring symptom frequency and intensity. Yields PTSD diagnoses and severity scores (0-80); considered most definitive assessment for trauma-related anxiety disorders.

An anticonvulsant (Tegretol) used for bipolar disorder and seizures. Strong CYP3A4 inducer affecting metabolism of many other medications.

A class of neurotransmitters that includes dopamine and norepinephrine (and epinephrine). Synthesized from the amino acid tyrosine. These chemicals are essential for prefrontal cortex function and are the primary targets of ADHD medications. PFC performance follows an inverted-U curve for catecholamine levels.

The chemical family of neurotransmitters that includes dopamine and norepinephrine. Central to understanding conditions involving attention, motivation, and executive function.

A deep brain structure involved in regulating motor activity and cognitive control.

Child Behavior Checklist. A broadband rating scale screening for emotional and behavioral problems in children and adolescents.

Cannabidiol; non-psychoactive cannabis compound with anxiolytic properties in preclinical models. Human evidence is limited to small trials; mechanism likely involves 5-HT1A partial agonism and endocannabinoid modulation. Not FDA-approved for anxiety; quality control and drug interaction concerns remain.

Cognitive Behavioral Therapy. An evidence-based psychotherapy approach that targets maladaptive thought patterns and behaviors.

The point at which increasing the dose or intensity of a measure no longer produces additional effect.

A brain region traditionally associated with motor coordination, now known to contribute to cognitive timing and error correction.

Center for Epidemiologic Studies Depression Scale. A screening tool for depressive symptoms.

Carboxylesterase 1. The liver enzyme primarily responsible for metabolizing methylphenidate. Genetic variants affect drug levels.

Children's Global Assessment Scale. A clinician-rated measure of overall functioning in children.

Clinical Global Impressions-Severity scale. A clinician-rated measure of overall symptom burden, scored from 1 (not ill) to 7 (extremely ill).

The legal obligation under IDEA for schools to identify, locate, and evaluate all children with suspected disabilities.

A healthcare framework for managing long-term conditions through ongoing monitoring and collaborative care.

Confidence Interval. A statistical range expressing the precision of an estimate, typically at 95% confidence.

Relating to biological rhythms that follow an approximately 24-hour cycle, most notably the sleep-wake cycle. Circadian disruption is common in ADHD and can worsen inattention and emotional dysregulation.

A biological shift toward later sleep-wake timing.

An SSRI antidepressant (Celexa) used for depression and anxiety. Has a dose-dependent risk of QTc prolongation, which strictly limits maximum doses, especially in older adults.

A pharmacokinetic measure of how efficiently the body removes a drug from the bloodstream.

Whether a statistical finding is large enough to matter in real-world patient care.

An improvement large enough to make a noticeable difference in a patient's daily functioning.

Tricyclic antidepressant with potent serotonin and norepinephrine reuptake inhibition; FDA-approved for OCD and off-label for anxiety disorders. Higher anticholinergic burden limits tolerability compared to modern SSRI/SNRI agents.

Long-acting benzodiazepine (half-life 18-50 hours) used for anxiety and panic. Lower abuse potential than shorter-acting agents but carries risks of dependence, cognitive impairment, and falls, especially in older adults.

Alpha-2 adrenergic agonist reducing sympathetic outflow. In anxiety contexts, used off-label for autonomic hyperarousal symptoms (tachycardia, tremor, diaphoresis) and as a non-addictive alternative for acute anxiety when benzodiazepines are contraindicated.

Central nervous system; the brain and spinal cord. CNS-active medications cross the blood-brain barrier and affect neural function.

A systematic review published by the Cochrane Collaboration, considered among the highest quality evidence summaries.

A necessary helper molecule that an enzyme requires to function. Iron is a cofactor for tyrosine hydroxylase, the enzyme that produces dopamine. Iron deficiency can impair dopamine synthesis and worsen ADHD symptoms.

Wells's metacognitive model describing pathological cycle of worry, rumination, threat monitoring, and maladaptive coping strategies that perpetuate GAD through negative metacognitive beliefs about worry itself.

A structured psychotherapy that targets maladaptive thought patterns and behaviors through skills training, cognitive restructuring, and behavioral activation. Used in ADHD primarily for comorbid anxiety, depression, and as an adjunct for organizational skills.

ACT and mindfulness-based technique where patient creates psychological distance from distressing thoughts by observing them as mental events (like watching clouds pass in sky) rather than facts to be argued with or believed. Disrupts the thought-anxiety feedback cycle.

A CBT technique that identifies and challenges distorted thinking patterns.

A measure of effect size expressing the difference between two group means in standard deviation units.

Occurring alongside another condition in the same individual. ADHD has high comorbidity rates: roughly two-thirds of children with ADHD meet criteria for at least one additional psychiatric diagnosis.

The co-occurrence of two or more diagnoses in the same patient. In psychiatry, comorbidity is common and significantly affects treatment planning.

A behavioral disorder characterized by persistent violation of societal norms and the rights of others.

A range of values within which the true population parameter is likely to fall, typically at 95% confidence.

A behavioral approach using structured rewards and consequences to shape behavior.

A vision disorder that makes near-work painful and is often mistaken for inattention.

Manualized cognitive-behavioral program for anxiety prevention and early intervention in young children (ages 4-8), emphasizing emotion regulation, social skills, and behavioral management strategies.

Empirically-supported CBT protocol for childhood anxiety disorders (ages 8-13) combining exposure, cognitive strategies, and coping skills. Core acronym FEAR: Feeling, Expecting, Attitudes, Results.

Continuous Performance Test. A computerized test measuring sustained attention and impulse control.

A screening tool for substance use risk in adolescents, useful in comprehensive psychiatric assessment.

Corticotropin-releasing hormone; neuropeptide released by hypothalamus that initiates the HPA axis stress cascade by stimulating pituitary ACTH release, which triggers adrenal cortisol secretion. In anxiety disorders, chronic CRH elevation drives persistent HPA axis activation; CRF1 receptor antagonists were developed to block this but failed clinically.

The normal discrepancy between different raters (e.g., parent vs. teacher) when reporting on the same patient.

A clinical trial design in which each participant receives both the experimental and control treatments in sequence, serving as their own control. Reduces between-subject variability but requires a washout period between conditions.

Cytochrome P450 1A2. A liver enzyme metabolizing caffeine and some antipsychotics (notably olanzapine and clozapine). Activity is significantly increased by tobacco smoking, which can lower medication levels.

Cytochrome P450 2D6. A liver enzyme involved in metabolizing many psychotropic medications. Genetic variants and drug interactions affect medication levels.

Cytochrome P450 3A4. The most abundant liver enzyme, responsible for metabolizing many psychiatric medications.

A family of liver enzymes (designated CYP followed by numbers and letters, such as CYP2D6 or CYP3A4) responsible for metabolizing most psychiatric medications. Genetic variation in cytochrome enzymes is a major source of individual differences in drug response.

Antibiotic acting as partial N-methyl-D-aspartate (NMDA) receptor agonist; shown in meta-analyses to enhance extinction learning when given before exposure therapy, approximately doubling the effect size. Enhancement effect appears larger for specific phobias and social anxiety than for PTSD.

Daily Behavior Report Card. A school-based monitoring tool linking classroom behavior to home consequences.

Dialectical Behavior Therapy. A therapy combining cognitive-behavioral techniques with mindfulness, particularly useful for emotional dysregulation.

Developmental Coordination Disorder. A motor skills condition causing clumsiness and difficulty with fine and gross motor tasks.

A brain network active during mind-wandering and self-referential thought. Shows abnormal connectivity in several psychiatric conditions.

A mood disorder characterized by persistent low mood, loss of interest or pleasure, and associated cognitive and physical symptoms. Major depressive disorder is a common comorbidity in ADHD, particularly in adolescents and adults.

A tricyclic antidepressant sometimes used off-label for attention and mood disorders, and neuropathic pain. Works via norepinephrine reuptake inhibition.

Deficient Emotional Self-Regulation. A framework describing emotional dysregulation as a core feature of certain conditions.

Wells's metacognitive therapy technique where patient observes intrusive thoughts as passing mental events (like watching train pass platform) without engaging, suppressing, analyzing, or distracting. Anti-thought-control intervention.

The expected pattern of skill acquisition and behavioral change across childhood and adolescence.

South Asian (primarily Indian) cultural anxiety syndrome presenting as fatigue, weakness, and sexual dysfunction attributed to loss of semen (dhat) through nocturnal emissions or masturbation. Culturally embedded health concern; anxiety about sexual function drives symptom presentation.

When a prominent diagnosis causes clinicians to attribute new symptoms to the existing condition rather than considering additional diagnoses.

The degree to which a diagnosis remains consistent over time across repeated assessments.

Long-acting benzodiazepine with extended half-life (20-70 hours) and active metabolites; historically used for acute anxiety and alcohol withdrawal. Now largely superseded by newer agents in clinical practice.

The systematic process of distinguishing between conditions that share similar symptoms.

The time at which endogenous melatonin levels begin rising under dim lighting conditions. A reliable biomarker of circadian phase used clinically to guide the timing of melatonin supplementation. Abbreviated DLMO.

First-generation antihistamine (Benadryl) with anticholinergic properties sometimes used as a sleep aid. Not recommended for anxiety due to cognitive impairment, tolerance, anticholinergic burden, and association with increased dementia risk with long-term use in older adults.

Physical and psychological symptoms arising from abrupt cessation or rapid tapering of psychotropic medications (particularly SNRIs), including dizziness, electric shock-like sensations, nausea, insomnia, and dysphoria. More severe with drugs having shorter half-lives and higher potency; managed by slow tapering schedules.

A structured period off medication to assess whether ongoing treatment is still necessary.

A childhood condition characterized by severe, recurrent temper outbursts and persistent irritable or angry mood between outbursts. Introduced in DSM-5 to address concerns about overdiagnosis of pediatric bipolar disorder. Abbreviated DMDD.

A disconnection from one's thoughts, feelings, surroundings, or identity, often associated with trauma.

Dim light melatonin onset. The time at which endogenous melatonin levels begin rising under dim lighting conditions. Used as a reliable biomarker for circadian phase and to guide the timing of exogenous melatonin administration.

Disruptive mood dysregulation disorder. A childhood condition characterized by severe, recurrent temper outbursts and persistent irritable or angry mood between outbursts. Introduced in DSM-5 to address concerns about overdiagnosis of pediatric bipolar disorder.

An epigenetic mechanism where methyl groups attach to DNA, typically silencing gene expression without changing the DNA sequence. Environmental exposures (stress, toxins, nutrition) can alter methylation patterns, providing a molecular pathway by which experience shapes gene expression across the lifespan.

A neurotransmitter central to reward, motivation, and executive function. Key pathways: mesocortical (ventral tegmental area → prefrontal cortex, involved in attention and working memory), mesolimbic (VTA → nucleus accumbens, involved in reward and motivation), and nigrostriatal (substantia nigra → striatum, involved in motor control). The primary target of stimulant medications in ADHD.

Prefrontal region that amplifies threat detection and monitors for danger; elevated dACC activity appears across GAD and social anxiety disorder, correlating with tendency to scan for potential threats.

The region of the prefrontal cortex most associated with working memory and cognitive control.

The relationship between a medication dose and the magnitude of its therapeutic or adverse effects.

A study design where neither participants nor researchers know which intervention each participant is receiving.

Tricyclic antidepressant with potent antihistamine (H1) antagonism; used off-label at very low doses (3-6 mg at bedtime) for insomnia in anxious patients due to sedating properties. Higher doses (25+ mg) provide serotonergic antidepressant effects but with pronounced anticholinergic burden.

A planned period off medication, used to reassess ongoing need, evaluate side effects, or allow physiological recovery.

When one medication affects the metabolism, absorption, or action of another medication.

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (2022). The standard classification system for psychiatric diagnoses in the United States.

Diffusion Tensor Imaging. A neuroimaging technique that maps white matter pathways in the brain.

A formal legal proceeding to resolve disputes between families and schools about special education services.

An SNRI antidepressant (Cymbalta) used for depression, anxiety, and chronic pain conditions. Also approved for stress urinary incontinence.

Dual-energy X-ray Absorptiometry. A scan measuring bone density, sometimes relevant for monitoring growth during medication treatment.

A clinical term for Specific Learning Disorder with impairment in mathematics, affecting number sense, calculation, and mathematical reasoning.

A clinical term for difficulties with written expression, particularly affecting handwriting, spelling, and the mechanics of getting thoughts onto paper.

A state of pronounced unease, irritability, or emotional discomfort.

A group of conditions characterized by persistent disturbances in eating behavior and related distress.

Electrocardiogram. A test recording the heart's electrical activity, sometimes recommended before starting medications that may affect cardiac rhythm.

Electroencephalogram. A test that records electrical activity in the brain.

A statistical measure of the magnitude of a difference between groups or a relationship between variables.

Eye Movement Desensitization and Reprocessing; psychotherapy protocol for post-traumatic stress and trauma-related anxiety disorders involving bilateral stimulation (eye movements, tapping, or tones) paired with trauma processing. Mechanism remains debated; efficacy for PTSD is established though equivalent to prolonged exposure.

Difficulty managing emotional responses: quick to anger, easily frustrated, intense reactions.

Mirror-image forms of the same molecule with different pharmacological activity.

Chemical modifications that change gene expression without altering the DNA sequence itself. Environmental exposures like stress or toxins can create epigenetic changes that affect brain development and may contribute to ADHD risk.

Exposure and Response Prevention. The first-line behavioral therapy for OCD, involving gradual confrontation with feared stimuli.

An SSRI antidepressant (Lexapro) widely used for anxiety disorders and depression. Better tolerated than some earlier SSRIs with minimal drug interactions.

S-enantiomer of ketamine (the more potent form) approved by FDA via intranasal route for treatment-resistant depression; FDA approval for anxiety disorders has not yet occurred. Shows rapid onset compared to SSRIs; controlled substance requiring supervised administration.

A set of cognitive processes including working memory, flexible thinking, and self-control.

Core mechanism of inhibitory learning model; occurs when feared catastrophic prediction fails to materialize during exposure, forcing brain to update threat assessment and build competing safety memory.

Ranked list of anxiety-provoking situations arranged from least to most threatening, used to structure gradual exposure therapy progression. Allows therapist and patient to work systematically from manageable to more challenging exposures.

Gold-standard psychotherapy approach systematically confronting feared situations or stimuli to disconfirm catastrophic predictions and build safety memories. Forms active ingredient across most evidence-based anxiety treatments.

Functional classification grouping the amygdala and BNST together due to shared neurochemistry and interconnectivity, though they perform functionally distinct roles in acute fear versus sustained anxiety.

A testing accommodation providing additional time to complete assessments.

A medication formulation designed to release its active ingredient gradually over an extended period, typically 8 to 16 hours. Reduces dosing frequency and provides smoother symptom coverage throughout the day.

Outwardly directed behavioral problems including aggression, defiance, and hyperactivity.

The gradual disappearance of a learned behavior when its reinforcement is removed. Typically preceded by an 'extinction burst' where the behavior temporarily intensifies before improving.

Neurobiological process by which the brain learns that a previously feared stimulus is now safe, mediated by ventromedial prefrontal cortex (vmPFC) building a competing safety memory. Forms the core neural mechanism underlying exposure therapy.

Free Appropriate Public Education. The legal standard under IDEA requiring schools to provide education tailored to students with disabilities at no cost.

Functional Assessment Staging Tool; originally developed for dementia but adapted for measuring functional impact of anxiety and mood disorders on activities of daily living, cognition, and social participation. Emphasizes staged progression of functional decline.

Functional Behavioral Assessment. A systematic process for identifying the function of problem behaviors, used to develop intervention plans.

U.S. Food and Drug Administration. The federal agency responsible for approving medications and medical devices.

A regulatory pathway (510(k)) in which the FDA determines a medical device is substantially equivalent to an existing approved device. FDA clearance is a lower bar than FDA approval and does not require clinical trials demonstrating efficacy. Important distinction when evaluating marketed ADHD diagnostic devices.

Neurobiological process by which neutral stimulus becomes associated with danger through classical conditioning, resulting in conditioned fear response. Forms basis for understanding phobic learning and anxiety acquisition.

Neurobiological process by which brain learns that previously threatening stimulus is now safe, mediated by ventromedial prefrontal cortex building competing safety memory. Forms neural basis for all exposure therapy.

Primary evidence-based treatment choice for an anxiety disorder, recommended as the initial intervention based on clinical trial data and treatment guidelines. SSRIs/SNRIs and CBT are first-line for most anxiety disorders; benzodiazepines are not.

The initial processing of an oral drug by the liver before it reaches systemic circulation. Some drugs lose a substantial fraction of their dose during this process, reducing bioavailability.

An SSRI antidepressant (Prozac). Widely used for depression, anxiety, and OCD. A strong CYP2D6 inhibitor relevant to many medication interactions.

An SSRI used primarily for OCD and anxiety disorders. Notable as a strong CYP1A2 and CYP2C19 inhibitor affecting multiple drug metabolic pathways.

Functional Magnetic Resonance Imaging. A neuroimaging technique that measures brain activity by detecting blood flow changes.

Fear Questionnaire; 17-item self-report measuring phobic anxiety across three domains: agoraphobia, social phobia, and blood-injury phobia. Designed specifically for specific phobias and social anxiety. Total score range varies by domain; emphasizes avoidance and distress.

A neuroimaging measurement from diffusion tensor imaging (DTI) that indicates how organized white matter tracts are. Higher values indicate more organized, intact connections; lower values suggest degraded wiring.

A systematic process for identifying the triggers and consequences maintaining a problem behavior.

The real-world impact of symptoms on daily life, including school, work, relationships, and self-care.

Gamma-aminobutyric acid. The brain's primary inhibitory neurotransmitter. Reduces neuronal excitability throughout the nervous system. Relevant to ADHD through its role in impulse control circuits and as the target of some medications used for comorbid conditions (anxiety, insomnia).

Anticonvulsant with anxiolytic properties via calcium channel modulation; off-label for anxiety and social phobia. Limited evidence compared to SSRIs; carries risk of abuse and dependence in susceptible populations.

Generalized Anxiety Disorder. A condition characterized by persistent, excessive worry across multiple life domains.

Two-item ultra-brief screener derived from GAD-7; score of 3 or higher yields 86% sensitivity and 83% specificity for GAD, used as pre-screener triggering full GAD-7 assessment.

Generalized Anxiety Disorder 7-Item Scale; most widely used anxiety screener globally. Rates seven core anxiety symptoms over past two weeks on 0-3 scale. Cutoff 5=mild, 10=moderate, 15=severe; score 10 yields 89% sensitivity and 82% specificity for GAD.

Global Assessment of Functioning. A clinician-rated scale of overall psychological, social, and occupational functioning (0-100 scale).

The transfer of skills learned in one setting (e.g., therapy) to other real-world environments.

An anxiety disorder characterized by persistent, excessive worry across multiple life domains.

Anxiety disorder characterized by excessive, uncontrollable worry occurring most days for at least six months (one symptom in children), accompanied by at least three of: restlessness, fatigue, difficulty concentrating, irritability, muscle tension, or sleep disturbance.

When an apparent environmental risk factor for a condition actually reflects shared genetic influences. For example, prenatal smoking correlates with ADHD, but this may reflect inherited traits (impulsivity, risk-taking) that both increase smoking likelihood and ADHD risk, rather than a direct causal effect of smoking on the developing brain.

The brain's primary excitatory neurotransmitter. Involved in learning, memory, and synaptic plasticity. Emerging research suggests glutamatergic dysfunction may contribute to ADHD pathophysiology, particularly in cortico-striatal circuits.

Exposure therapy conducted systematically from least to most anxiety-provoking situations using a hierarchical exposure hierarchy, allowing patients to practice extinction learning incrementally. Also called graded exposure; distinct from single-session massed exposures or prolonged immersion techniques.

The rate of height or weight gain over time, used to monitor potential medication effects on development.

Genome-Wide Association Study. A research method scanning entire genomes to find genetic variants associated with a trait or disorder.

Gene-Environment Interaction. The concept that genetic predisposition and environmental factors jointly influence disease expression.

The time it takes for the body to clear half the drug from the bloodstream. Influences how long a medication remains active, though clinical effects of some drugs can outlast their blood levels.

Hamilton Anxiety Rating Scale; 14-item clinician-rated assessment of anxiety symptom severity scored 0-56. Score 17 indicates mild anxiety, 25 moderate, 30+ severe. Widely used in treatment trials but criticized for psychomotor item emphasis; ADIS-5 increasingly preferred for disorder-specific diagnosis.

A measure of how much a factor increases or decreases risk over time.

Healthcare Effectiveness Data and Information Set. A set of quality measures used to evaluate healthcare performance.

Liver damage caused by medications or other substances.

The proportion of variation in a trait that is attributable to genetic differences within a population.

In meta-analysis, the degree of variability in study results beyond what would be expected by chance.

A brain structure essential for memory formation and spatial navigation.

Hierarchical Taxonomy of Psychopathology. A dimensional diagnostic framework that organizes mental health conditions along continuous spectra rather than discrete categories, which may better capture the reality of conditions like ADHD.

Hypothalamic-Pituitary-Adrenal axis. The body's central stress response system.

Korean cultural syndrome translating as 'anger syndrome,' presenting with suppressed anger, physical symptoms (chest tightness, heat sensations, fatigue), and anxiety. Reflects cultural norms against emotional expression; recognized in DSM-5 appendix as culturally specific anxiety-related presentation.

Antihistamine with anticholinergic and anxiolytic properties; used as short-term bridging agent during SSRI initiation or for acute anxiety. Onset 15-30 minutes; non-habit-forming but produces sedation.

A state of heightened alertness and scanning for threats.

Abnormally low blood sodium concentration (below 135 mEq/L). An uncommon but potentially dangerous adverse effect of SSRIs and SNRIs, particularly in elderly patients. Presents with confusion, nausea, headache, and in severe cases seizures.

International Classification of Diseases, 11th Revision (2022). The WHO's global diagnostic classification system used in most countries.

Individuals with Disabilities Education Act. Federal law requiring schools to provide free appropriate public education (FAPE) to eligible students with disabilities.

Individualized Education Program. A legally binding document under IDEA that provides specialized instruction and services for students with disabilities.

A tricyclic antidepressant used for depression, anxiety, and nocturnal enuresis. An older medication that has fallen out of favor due to more modern alternatives.

A medication formulation that releases its full dose shortly after ingestion, typically providing 3 to 6 hours of effect. Offers dosing flexibility but requires multiple daily doses for sustained coverage.

Exposure therapy conducted in real-world settings with actual feared situations or objects, rather than in imagination or office setting. Generally produces stronger extinction learning than imaginal or virtual exposures.

The rate of new cases of a condition occurring in a population over a specified time period. Distinct from prevalence, which counts all existing cases regardless of when they began.

The process by which a patient (or legal guardian) receives and understands information about a proposed treatment's benefits, risks, alternatives, and right to refuse, then voluntarily agrees to proceed. Required before initiating any medication trial.

Craske's neurobiological model of exposure therapy explaining that anxiety reduction is mediated by creation of competing safety memory through expectancy violation, not by erasure of original fear memory.

Brain region responsible for interoception (conscious awareness of internal body states like heartbeat, breathing, gut sensations). Overactivity in anxiety disorders leads to amplification and catastrophic misinterpretation of normal bodily signals.

A neurodevelopmental disorder characterized by significant limitations in intellectual functioning and adaptive behavior.

Inwardly directed emotional problems including anxiety, depression, and withdrawal.

Exposure therapy component deliberately inducing feared physical sensations (dizziness, rapid heart rate, breathlessness) to teach patient brain that these sensations are harmless. Core component of panic disorder treatment.

A framework for understanding how overlapping social identities (race, gender, disability, socioeconomic status) interact to create unique experiences of disadvantage or discrimination.

Dugas's model positing that individuals with GAD possess dispositional vulnerability with strongly negative beliefs about uncertainty itself. Drives excessive reassurance-seeking, information gathering, and worry across domains.

The dose-response relationship where both too little and too much of a neurotransmitter impair function. Optimal performance occurs at intermediate levels.

Incidence Rate Ratio. A measure comparing the rate of events between exposed and unexposed groups in epidemiological studies.

A heightened proneness to anger or frustration, seen across many psychiatric conditions.

Intention-to-Treat analysis. A method analyzing all participants as originally assigned, regardless of adherence or protocol completion.

NMDA receptor antagonist showing rapid anxiolytic and antidepressant effects in treatment-resistant populations, particularly depression. Evidence for primary anxiety disorders (GAD, social anxiety, panic) remains sparse; no FDA approval for anxiety. Abuse liability and dissociative side effects limit routine use.

Cambodian cultural anxiety syndrome translating as 'wind overload,' characterized by sudden panic/dizziness episodes attributed to wind or air rising in the body. Somatic focus (head, neck, upper torso) and orthostatic dizziness distinguish from Western panic disorder; common in trauma survivors.

Amino acid found in green tea that promotes relaxation via alpha-wave enhancement and partial glutamate receptor antagonism. Limited but emerging evidence for mild anxiolytic effects at 200-400 mg/day. Generally well-tolerated; not a substitute for evidence-based treatments.

An anticonvulsant and mood stabilizer (Lamictal) particularly effective for bipolar depression. Slow titration required to minimize rash risk.

A mood stabilizer used for bipolar disorder maintenance and acute mania. Narrow therapeutic window requiring regular blood level monitoring.

Brainstem nucleus containing ~40,000-60,000 neurons serving as primary source of brain norepinephrine. Projects to nearly all brain regions; chronic stress shifts firing from adaptive phasic bursts to pathological tonic firing driving hyperarousal.

A research design that follows the same participants over an extended period to track changes and outcomes.

Intermediate-acting benzodiazepine (half-life 10-20 hours) with minimal hepatic metabolism, suitable for patients with liver disease. Used acutely for anxiety and agitation; carries standard BZD risks.

Least Restrictive Environment. The IDEA principle that students with disabilities should be educated with non-disabled peers to the maximum extent appropriate.

Liebowitz Social Anxiety Scale; 24-item measure rating fear and avoidance separately for social interaction and performance situations. Severity: 30-49 mild, 50-64 moderate, 65-79 marked, 80+ severe.

The ongoing treatment period after initial stabilization, focused on sustaining gains and preventing relapse.

A mood disorder characterized by persistent sad mood or loss of interest, with functional impairment.

Monoamine Oxidase. An enzyme that breaks down neurotransmitters (dopamine, norepinephrine, serotonin) inside neurons.

Monoamine Oxidase Inhibitor. A class of antidepressant medications rarely used due to dietary restrictions and interaction risks.

Multidimensional Anxiety Scale for Children, 2nd Edition; 50-item proprietary tool for ages 8-19 with Anxiety Probability Score and dedicated GAD Index. T-scores 65-69 subclinical, 70+ clinically significant.

Consciously or unconsciously concealing symptoms to appear neurotypical, common in certain populations.

3,4-methylenedioxymethamphetamine; research demonstrating efficacy when combined with psychotherapy for PTSD in breakthrough therapy trials, showing 71-73% remission rates. Proposed mechanism: enhances therapeutic alliance, promotes emotional processing, and reduces threat vigilance. Still Schedule I; MAPS sponsoring FDA trials.

Manifestation Determination Review. A process to determine whether a student's behavior is related to their disability before disciplinary action.

Systematic clinical practice of administering validated patient-reported outcome measures at regular intervals to track symptom trajectory and inform treatment adjustments collaboratively. Components include: measure administration, clinician review, patient-clinician discussion, and documented treatment modification based on symptom progress.

Routine, systematic evaluation of patient symptoms using validated patient-reported outcome measures to inform treatment decisions. Four-component process: administer measures, practitioner review, collaborative discussion, mutual treatment adjustment.

A hormone supplement commonly used to address sleep difficulties associated with psychiatric conditions and medications.

A research method that uses genetic variants as natural experiments to test whether an exposure (like smoking or lead) truly causes an outcome (like ADHD), rather than just correlating with it. Helps distinguish genuine environmental risk factors from genetic confounding.

A statistical method that combines results from multiple studies to produce a more precise estimate of a treatment's effect.

A substance produced when the body chemically processes (metabolizes) a drug or other compound. Metabolites may be active, inactive, or potentially harmful, and their levels can vary depending on individual enzyme activity.

A person's drug-processing capacity based on their genetic enzyme activity (poor, intermediate, normal, ultrarapid).

Wells's treatment targeting patient's beliefs about worry (Type 2 worry) rather than worry content itself. Uses detached mindfulness and worry postponement to alter negative metacognitive beliefs about worry control.

Extended-release methylphenidate using a beaded system with a 30:70 immediate-to-delayed release ratio.

Atypical antidepressant (NaSSA) blocking alpha-2 autoreceptors and 5-HT2A/2C/3 receptors while antagonizing histamine H1 receptors. Primary niche: anxious depression with severe insomnia or anorexia (where side effects become therapeutic assets); not first-line for uncomplicated anxiety. Dose paradox: more sedating at lower doses.

A wakefulness-promoting agent sometimes used off-label for attention disorders and excessive daytime sleepiness.

A change to what a student is expected to learn or demonstrate, altering content or performance standards. Contrast with accommodation, which changes how material is delivered without altering expectations.

Therapeutic approach using motivational interviewing techniques to increase client intrinsic motivation for behavior change and treatment adherence. Involves exploring ambivalence, eliciting change talk, and supporting autonomy rather than directive advice-giving.

A collaborative conversation style that strengthens a person's own motivation for and commitment to change.

Multi-Tiered Systems of Support. A framework providing increasingly intensive interventions based on student needs.

Gathering diagnostic information from multiple sources to improve accuracy.

A rating scale designed to measure symptoms of a specific disorder.

Noradrenergic and Specific Serotonergic Antidepressant. A drug class represented by mirtazapine, which blocks alpha-2 autoreceptors and specific serotonin receptors (5-HT2A, 5-HT2C, 5-HT3) to enhance norepinephrine and serotonin transmission.

Antidepressant with serotonergic and noradrenergic effects and 5-HT2A receptor antagonism; discontinued in United States due to hepatotoxicity risk but available in other markets. Historical use in anxiety; minimal sexual side effects. Black box warning for liver injury.

The probability that a negative test result correctly identifies someone who does not have the condition.

Spanish cultural idiom for anxiety/stress presenting as physical symptoms (trembling, heart palpitations, weakness) and emotional distress (worry, difficulty concentrating). Recognition of this cultural expression prevents misdiagnosis and improves engagement with Latino/Latinx patients experiencing anxiety.

Norepinephrine Transporter. The protein that recycles norepinephrine from the synapse. Blocked by both stimulants and some non-stimulants.

A method that compares multiple treatments simultaneously by linking all available trials.

A category of conditions with onset during the developmental period, arising from differences in brain maturation. Includes ADHD, autism, intellectual disability, and learning disorders.

The pattern of brain maturation and cognitive development from early childhood through young adulthood.

Brain-based biofeedback where fMRI or EEG data show real-time neural activity, allowing patients to self-regulate brain regions implicated in anxiety (e.g., amygdala hyperactivation). Efficacy for anxiety remains investigational; mechanism and optimal targets under active research.

The brain's ability to reorganize and form new neural connections throughout life in response to experience.

Natural steroid hormones produced by the body (particularly allopregnanolone from progesterone metabolism) that modulate extrasynaptic GABA-A receptors, providing baseline neural inhibition independent of synaptic transmission. Zuranolone, an oral synthetic neurosteroid, FDA-approved for postpartum depression, demonstrates mechanism distinct from benzodiazepines.

A chemical messenger released by neurons to transmit signals across synapses. The neurotransmitters most relevant to ADHD are dopamine and norepinephrine (catecholamines), which regulate prefrontal cortex function, reward processing, and attention.

National Institute for Health and Care Excellence (UK). Publishes evidence-based guidance for mental health and neurodevelopmental disorder management.

National Institute for Health and Care Excellence clinical guidelines from United Kingdom synthesizing evidence for mental health conditions including anxiety disorders, influential internationally. NICE CG113 specifically addresses anxiety disorder assessment and management.

National Institute of Mental Health. The lead U.S. federal agency for research on mental disorders.

Number Needed to Harm. The number of patients who must receive a treatment for one additional patient to experience a specific adverse effect.

Number Needed to Treat. The number of patients who must receive a treatment for one additional patient to benefit compared to placebo. Lower is better.

Failure to follow a prescribed treatment regimen, whether by missing doses, stopping medication early, or not attending therapy sessions. Common in ADHD and associated with poorer outcomes. Often driven by side effects, forgetfulness, stigma, or cost.

A medication used to treat ADHD that does not belong to the stimulant class. Includes atomoxetine, guanfacine, clonidine, and viloxazine. Often considered when stimulants are ineffective, poorly tolerated, or contraindicated.

A neurotransmitter involved in attention, arousal, and the stress response. Key pathway: locus coeruleus → widespread cortical projections, especially prefrontal cortex. Strengthens signal in PFC networks by acting on α2A-adrenoceptors. Targeted by atomoxetine, guanfacine, and clonidine. Under high stress, excess norepinephrine activates α1 receptors that degrade PFC function.

A tricyclic antidepressant used for depression, anxiety, and chronic pain conditions. Metabolite of amitriptyline with improved side effect profile.

Relating to the classification of diseases and disorders. A nosological question asks whether a condition belongs in the diagnostic system as its own distinct entity.

The brain's reward center, which drives motivation and is central to understanding reward processing and motivation across conditions.

A sleep disorder where the airway repeatedly collapses during sleep, causing fragmented sleep and daytime impairment.

Obsessive-Compulsive Disorder. A condition involving intrusive thoughts (obsessions) and repetitive behaviors (compulsions).

Obsessive-Compulsive Inventory-Revised; 18-item self-report measuring OCD symptom severity across six domains (obsessing, checking, hoarding, ordering, washing, neutralizing). Total score 0-72; cutoff 21 indicates clinically significant OCD; useful in mixed anxiety presentations.

Oppositional Defiant Disorder. A behavioral disorder characterized by angry/irritable mood, argumentative/defiant behavior, and vindictiveness.

A measure of association between an exposure and an outcome, commonly used in case-control studies.

Prescribing an FDA-approved medication for a condition, age group, or dose not specified in its official labeling.

Other Health Impairment. An IDEA eligibility category for students whose health conditions—including heightened alertness to environmental stimuli—adversely affect educational performance.

An atypical antipsychotic (Zyprexa) used for bipolar disorder and psychosis. Higher metabolic risk (weight gain, diabetes) than some other antipsychotics.

A study design in which both the researcher and participant know which treatment is being administered. Useful for assessing real-world tolerability and long-term safety but more vulnerable to expectancy bias than blinded designs.

A learning process where the likelihood of a behavior changes based on its consequences—increasing with reinforcement and decreasing with punishment.

A behavioral disorder characterized by a pattern of angry/irritable mood, argumentative behavior, and defiance toward authority figures.

A prefrontal region involved in decision-making, reward evaluation, and social behavior.

A drug delivery technology (used in OROS methylphenidate) that uses an osmotic gradient to push medication through a laser-drilled hole in an outer shell, producing a controlled ascending release profile over 10 to 12 hours.

Organizational Skills Training. A structured intervention teaching children and adolescents to manage materials, time, and task planning.

Abrupt surge of intense fear or discomfort peaking within minutes, with at least four somatic or cognitive symptoms: palpitations, sweating, trembling, shortness of breath, chest pain, dizziness, nausea, derealization, fear of dying, or fear of losing control.

Anxiety disorder characterized by recurrent unexpected panic attacks followed by at least one month of persistent anticipatory anxiety or behavioral changes (such as avoidance of situations associated with panic).

An SSRI antidepressant (Paxil) with notable strong CYP2D6 inhibitor properties, affecting metabolism of many other medications. Used for anxiety and depression.

Pediatric Anxiety Rating Scale; clinician-rated instrument synthesizing child, parent, and clinical observation into single severity metric. Cutoff 11.5 (5-item subscale) or 17.5 (7-item total) distinguishes anxious from non-anxious youth.

PTSD Checklist for DSM-5; 20-item self-report measuring PTSD symptom severity. Score 31-33 yields optimal sensitivity/specificity for PTSD diagnosis; widely used in primary care, VA, and research settings. Practical advantages: free, brief, valid across trauma types.

Prescription Drug Monitoring Program. A state database tracking controlled substance prescriptions to prevent misuse.

Panic Disorder Severity Scale; 7-item scale measuring panic frequency, distress, anticipatory anxiety, agoraphobic avoidance, interoceptive avoidance, and functional impairment. Score 9+ suggests assessment needed; 5 or below indicates remission.

Pediatric Quality of Life Inventory. A measure of health-related quality of life in children and adolescents.

Prefrontal cortex. The anterior region of the frontal lobe responsible for executive functions including sustained attention, working memory, behavioral inhibition, planning, and organization. Exquisitely sensitive to catecholamine levels, following an inverted-U dose-response curve.

How a drug affects the body, including its mechanism of action and therapeutic effects.

How a person's genetic makeup affects the way their body processes a drug.

How the body absorbs, distributes, metabolizes, and eliminates a drug. Determines how long and how strongly a medication works.

Brief, burst-like dopamine release that signals prediction errors and drives learning and reinforcement.

Monoamine oxidase inhibitor (MAOI) with strong evidence for social anxiety disorder and atypical depression. Requires dietary tyramine restriction and has significant drug interaction potential; reserved for treatment-resistant cases.

When a drug interaction changes a person's metabolizer status (e.g., converting a normal metabolizer to a functional poor metabolizer).

A presentation that looks identical to a disorder from the outside but has a different underlying cause.

The observable characteristics of an individual resulting from the interaction of genotype and environment. In clinical use, the pattern of symptoms and traits a person displays.

Patient Health Questionnaire-9. A brief screening and severity measure for depression.

Present Levels of Academic Achievement and Functional Performance. The IEP section documenting a student's current abilities and needs.

An inert substance or sham intervention administered in clinical trials to serve as a comparison against the active treatment. Allows researchers to distinguish true drug effects from psychological or contextual influences.

An improvement in symptoms attributable to the expectation of benefit rather than the treatment's specific mechanism.

A numerical summary of genetic risk for a condition based on the cumulative effect of multiple common gene variants.

An overnight sleep study that monitors breathing, oxygen levels, and brain activity during sleep.

The probability that a positive test result correctly identifies someone who has the condition.

The brain region behind the forehead responsible for attention, planning, working memory, and impulse control. Central to understanding many psychiatric conditions.

Anticonvulsant (Schedule V controlled substance) with FDA approval for GAD. Calcium channel modulator with anxiolytic, anticonvulsant, and analgesic properties. Typical dose 150-600 mg/day; carries abuse and dependence risk.

An automatic, reflexive behavioral response that occurs before conscious decision-making, such as blurting out an answer, grabbing an object, or interrupting a conversation. Suppressing prepotent responses requires intact behavioral inhibition.

The tendency to continue an unchanged medication regimen despite evidence that adjustment is needed.

The DSM-5 relabeling of disorder "subtypes" to "presentations", reflecting that they are fluid and can change over time.

The proportion of a population found to have a condition at a specific point in time (point prevalence) or over a defined period (period prevalence). Distinct from incidence, which counts new cases only.

Pro re nata (as needed). A dosing strategy where medication is taken only when symptoms arise rather than on a fixed schedule. Common for acute anxiety management with benzodiazepines or hydroxyzine.

A statistical technique that creates balanced comparison groups by matching treated and untreated participants on relevant characteristics.

Lipophilic beta-blocker crossing blood-brain barrier; used for performance anxiety (public speaking, musical performance) at 10-40 mg as-needed. Blocks peripheral somatic symptoms but ineffective for cognitive worry.

A study design that follows a defined group forward in time to observe outcomes.

Polygenic Risk Score. A numerical summary of genetic risk for a condition based on the cumulative effect of multiple common gene variants.

Apparent treatment failure that is actually caused by non-adherence, untreated comorbidities, or pharmacokinetic mismatch.

Sympathomimetic decongestant available over the counter that can trigger or worsen anxiety symptoms through noradrenergic activation. Important to screen for in patients presenting with new or worsening anxiety, particularly panic-like symptoms.

Psychoactive alkaloid from psilocybin-containing mushrooms; currently in Phase 2 clinical trials for anxiety disorders and PTSD with promising preliminary results, particularly when combined with psychotherapy. Mechanism involves neuroplasticity enhancement and fear circuit modulation; remains Schedule I with investigational status.

Penn State Worry Questionnaire; 16-item measure focused exclusively on pathological worry, the cognitive hallmark of GAD. Total score 16-80; cutoff 61-65 best discriminates GAD from other anxiety disorders.

Providing patients and families with information about a diagnosis, its treatment, and management strategies.

A structured academic and cognitive evaluation designed to identify specific learning disabilities.

Observable restlessness with purposeless or semi-purposeless motor activity driven by inner tension. Distinguished from akathisia (which is specifically medication-induced) and from anxiety-driven fidgeting.

Post-Traumatic Stress Disorder. A condition that can develop after exposure to traumatic events.

A deep brain structure involved in motor control and habit learning.

Corrected QT interval. A measurement on ECG related to heart rhythm. Prolongation is a safety concern with some medications.

Abnormal lengthening of the heart's electrical recovery interval, increasing risk of dangerous arrhythmias.

An atypical antipsychotic (Seroquel) used for bipolar disorder, psychosis, and as a sleep aid due to sedating properties. Lower risk of extrapyramidal side effects.

A study design in which participants are randomly assigned to receive either the experimental intervention or a control condition. Considered the gold standard for evaluating treatment efficacy because randomization minimizes selection bias.

Revised Children's Manifest Anxiety Scale, 2nd Edition; 49-item proprietary tool for ages 6-19 with yes/no format reducing cognitive load. Generates Total Anxiety score with three subscales: physiological anxiety, worry, social anxiety.

Randomized Controlled Trial. The gold standard study design for evaluating treatment efficacy.

Safety behavior where anxious person repeatedly asks for reassurance that threat won't occur. Perpetuates anxiety by preventing person from learning they can tolerate uncertainty; should be actively reduced in treatment.

A temporary flare of symptoms that are more intense than the person's unmedicated baseline, occurring as a medication wears off.

The return of symptoms after a period of improvement or remission.

A sustained period where symptoms fall below clinical thresholds and functional impairment is minimal.

A behavioral technique where a privilege or token is removed following an undesired behavior.

A neurological condition causing uncomfortable sensations and an urge to move the legs.

The process by which a presynaptic neuron recycles neurotransmitters from the synapse back into the cell.

A drug that blocks the transporter proteins responsible for recycling neurotransmitters, keeping them active in the synapse longer.

How rewarding or motivating the brain perceives a given task or stimulus to be.

The ratio of event probability in the exposed group to the unexposed group.

An atypical antipsychotic used for irritability, aggression, and psychotic symptoms across psychiatric conditions. Lower propensity for metabolic side effects than older antipsychotics.

The gold-standard framework in psychiatry for establishing whether a diagnosis is scientifically valid. The five criteria are: consistent clinical presentation across settings and cultures, familial aggregation, laboratory correlates, predictable course, and treatment response.

Response to Intervention. A multi-tiered approach to early identification and support of students with learning and behavior needs.

Repetitive Transcranial Magnetic Stimulation; neuromodulation technique applying magnetic pulses to scalp to modulate brain activity, typically targeting dorsolateral prefrontal cortex. FDA-approved for treatment-resistant depression; efficacy in anxiety disorders remains investigational with mixed results.

Research Units on Pediatric Psychopharmacology. NIMH-funded multi-site research network that conducted pivotal pediatric anxiety trials, including the fluvoxamine RCT establishing SSRI efficacy in childhood anxiety disorders (RUPP Anxiety Study Group, 2001).

Social Anxiety Disorder; marked, persistent fear of social or performance situations where the person may be scrutinized. Distinguished from shyness by functional impairment and avoidance behavior. Lifetime prevalence approximately 12%.

Action or object used to prevent or mitigate feared outcome or manage anxiety (carrying water during panic, avoiding eye contact in social situations). Prevents disconfirmation of catastrophic predictions and maintains anxiety-related avoidance.

External support structures that compensate for symptoms. When scaffolding is removed, symptoms become more apparent.

Screen for Child Anxiety Related Disorders. A screening tool for anxiety in children and adolescents.

Spence Children's Anxiety Scale; 44-item child self-report (38-item parent version) mapping six DSM categories: social phobia, panic/agoraphobia, GAD, OCD, separation anxiety, specific phobias. T-score 60-64 elevated, 70+ very high.

A DEA classification for drugs with high abuse potential but accepted medical use, requiring special prescribing controls.

Sheehan Disability Scale; 3-item measure assessing functional impairment across work, social life, and family/home domains on 0-10 scales. Total 0-30; emphasizes patient-defined impact on life functioning. Often used as composite measure of treatment response in anxiety trials.

Alternative evidence-based treatment for an anxiety disorder when first-line interventions have been inadequately trialed or failed. Examples include buspirone augmentation, alternative SSRI/SNRI agents, or specific psychotherapy protocols for particular presentations.

Childhood anxiety disorder characterized by consistent failure to speak in specific social situations (typically school) despite ability to speak in other contexts, lasting at least one month and causing significant functional impairment.

Selective MAO-B inhibitor at low doses (used for Parkinson's disease) that becomes a non-selective MAOI at higher doses. The transdermal patch (Emsam) bypasses dietary tyramine restrictions at the lowest dose, offering a theoretically safer MAOI option.

The ability of a test to correctly identify those who have a condition (true positive rate).

Excessive fear or worry about being separated from attachment figures.

Anxiety disorder, typically beginning in childhood, characterized by excessive fear when separated from attachment figures, with worry about harm befalling the caregiver, reluctance to leave home, and somatic complaints.

A neurotransmitter involved in mood regulation, anxiety, impulse control, and sleep. Key pathway: raphe nuclei → widespread projections throughout the cortex, limbic system, and brainstem. Primary target of SSRIs and SNRIs. Relevant to ADHD through comorbid mood and anxiety disorders.

A potentially life-threatening condition caused by excessive serotonin activity, characterized by agitation, rapid heart rate, fever, muscle rigidity, and clonus.

Serotonin reuptake transporter, the membrane protein that SSRIs and SNRIs target to block reuptake of serotonin from synaptic space back into presynaptic neurons, increasing serotonin availability. The 5-HTTLPR polymorphism in the gene encoding SERT has no validated clinical utility despite earlier candidate gene claims.

An SSRI antidepressant (Zoloft) commonly used for anxiety disorders, depression, OCD, and PTSD across age groups.

A collaborative process where clinicians and patients jointly make treatment decisions.

Syndrome of Inappropriate Antidiuretic Hormone secretion. A potentially serious adverse effect of SSRIs and SNRIs causing dilutional hyponatremia; risk is highest in elderly patients and those on diuretics.

In neuroscience, the clarity of relevant neural signals relative to background neural activity.

In vivo exposure therapy targeting specific social situations or locations within social anxiety disorder, as opposed to interoceptive or imaginal exposure. Patient remains in the feared social situation long enough for anxiety to naturally decrease through extinction learning.

Specific Learning Disorder. A neurodevelopmental disorder affecting the acquisition of academic skills despite adequate instruction.

The normal cycling through light sleep, deep sleep, and REM sleep throughout the night.

The time it takes to transition from full wakefulness to sleep after lights out. Prolonged sleep onset latency is a common side effect of stimulant medications and a frequent concern in ADHD management.

Sequential Multiple Assignment Randomized Trial. A study design that adapts treatment based on patient response at each stage.

Standardized Mean Difference. A measure of effect size: 0.2 = small, 0.5 = medium, 0.8+ = large.

Single Nucleotide Polymorphism. A variation at a single DNA position, the most common type of genetic variation.

Serotonin-Norepinephrine Reuptake Inhibitor. A class of antidepressants that block reuptake of both serotonin and norepinephrine.

An anxiety disorder characterized by intense fear of social situations and scrutiny by others.

A neurodevelopmental disorder affecting the acquisition of academic skills despite adequate instruction.

Anxiety disorder involving marked, persistent, irrational fear of a specific object or situation (animals, heights, blood/injection/injury, enclosed spaces, flying, natural environment) that triggers avoidance behavior.

The ability of a test to correctly identify those who do not have a condition (true negative rate).

Social Phobia Inventory; 17-item proprietary measure assessing fear, avoidance, and physiological distress in social situations. Cutoff 19 or higher distinguishes clinical social phobia from healthy controls.

Selective Serotonin Reuptake Inhibitor. A class of antidepressant medications commonly used for anxiety and depression.

Sequenced Treatment Alternatives to Relieve Depression. Landmark NIMH-funded trial (N=4,041) demonstrating that most patients require multiple treatment steps to achieve remission, with diminishing response rates at each step.

The point where the drug level in the blood stabilizes, meaning you can judge whether a dose is working. Reached after about 5 half-lives.

Treatment matching framework where intensity and invasiveness increase stepwise based on symptom severity and treatment response. Lower-intensity steps (psychoeducation, self-help) are offered first; progression to higher-intensity steps (full psychotherapy, medication) occurs only if lower steps prove insufficient.

A rare, severe skin reaction to medications requiring immediate medical attention.

A class of medications (methylphenidate and amphetamine formulations) that increase synaptic dopamine and norepinephrine by blocking reuptake transporters (DAT and NET). First-line pharmacotherapy for ADHD with the largest evidence base for efficacy.

Gradual exposure technique used in selective mutism treatment where anxiety-provoking social communication demands are introduced incrementally with temporary supports (writing instead of speaking, speaking only to familiar vs. unfamiliar people), then supports are systematically withdrawn.

A deep brain structure involved in reward, motivation, and habit formation. Includes the caudate nucleus and putamen.

A standardized assessment format where clinicians ask predetermined questions in a specific order to improve diagnostic reliability.

Substance Use Disorder. A diagnosis for problematic patterns of substance use leading to clinically significant impairment.

Thoughts about or preoccupation with ending one's own life, ranging from passive wishes to active planning.

A medication formulation that delivers its active ingredient at a controlled rate over a prolonged period, similar to extended-release. Often used interchangeably with extended-release in clinical literature.

A drug that stimulates the sympathetic nervous system (fight-or-flight response).

The junction between two neurons where chemical signals (neurotransmitters) are transmitted across a tiny gap from the sending cell to the receiving cell.

The amount of neurotransmitter present in the synapse and available to bind receptors.

A comprehensive, structured synthesis of all available evidence on a specific clinical question.

Rapid decrease in drug response after repeated doses within a short period.

Japanese cultural syndrome of intense fear that one's body/appearance/behavior offends or embarrasses others; distinct from DSM social anxiety disorder by focus on harm to others rather than personal embarrassment. Reflects Japanese cultural emphasis on interdependence and group harmony.

The gradual reduction of a medication dose over days or weeks rather than abrupt discontinuation. Tapering reduces the risk of withdrawal symptoms or rebound effects, particularly with alpha-2 agonists such as clonidine and guanfacine.

Tricyclic Antidepressant. An older class of antidepressants that block reuptake of norepinephrine and serotonin.

A substance that causes birth defects when exposure occurs during pregnancy.

Delta-9-tetrahydrocannabinol; primary psychoactive component of cannabis. At low doses may reduce anxiety; at higher doses or in vulnerable individuals reliably increases anxiety and can precipitate panic attacks. Chronic use associated with anxiety disorder onset, particularly in adolescents.

Quality of the working relationship between clinician and patient, characterized by agreed-upon treatment goals, collaboration on interventions, and mutual emotional connection. Strong alliance independently predicts better treatment outcomes across psychotherapy and pharmacotherapy.

The margin between an effective dose and a toxic dose. A narrow therapeutic index means a dangerously small margin.

The dose range between minimum effective concentration and toxic concentration.

Treatment approach pursued after first-line and second-line agents or therapies have been adequately trialed without remission. Often includes higher-dose augmentation, combination pharmacotherapy, or novel agents like ketamine or psychedelic-assisted therapies.

A neurological deficit in temporal processing. Not willful disregard for time, but genuine difficulty perceiving time intervals.

The process of gradually adjusting a medication dose to find the optimal balance between efficacy and side effects.

A reinforcement system where individuals earn tokens for desired behaviors that can be exchanged for rewards.

Baseline, sustained dopamine levels that set overall arousal and readiness for action.

A neurodevelopmental disorder characterized by multiple motor tics and at least one vocal tic persisting for more than one year.

Test of Variables of Attention. A continuous performance test measuring attention and impulse control.

The planned transfer of clinical responsibility from pediatric to adult healthcare providers.

MAOI with rapid onset and potent effects; reserved for treatment-resistant anxiety and depression. Requires dietary tyramine restriction and has substantial drug interaction potential; used only in specialized settings.

An event or series of events that is physically or emotionally harmful and has lasting adverse effects on functioning.

Sedating antidepressant with alpha-1 antagonism and weak SERT inhibition; primarily used off-label as sleep aid in anxious or depressed patients with insomnia. Evidence base for anxiety as primary treatment is limited; sedation is primary therapeutic lever in anxiety contexts.

Structured, evidence-based decision pathway guiding sequential treatment choices based on patient response at each step. Typically organized as first-line, second-line, and treatment-resistant options with defined criteria for advancing.

The degree to which an intervention is delivered as intended in its original design.

A clinically significant reduction in symptoms following an intervention.

Failure to achieve remission despite adequate trials (adequate dose, adequate duration per Domschke staging criteria) of at least two first-line or second-line psychopharmacological agents. Triggers evaluation for third-line strategies and reassessment of diagnosis.

A student who is both gifted and has a disability.

LeDoux's model distinguishing System 1 (subcortical survival circuit producing physical defensive responses) from System 2 (cortical consciousness network producing subjective feeling of fear). These systems can activate independently.

A white matter tract connecting emotion centers (amygdala, limbic structures) to self-regulation centers (prefrontal cortex). When degraded, the prefrontal cortex has reduced ability to modulate emotional reactions.

Transdiagnostic, modular CBT framework treating anxiety across diagnostic categories through common mechanisms: cognitive flexibility, emotional awareness, behavioral activation, and exposure-based learning.

An anticonvulsant and mood stabilizer (Depakote) used for bipolar disorder and seizure prevention. Requires monitoring for liver function and blood counts.

ACT core technique where patient identifies personally meaningful values (relationships, growth, creativity) and commits to concrete behavioral steps aligned with those values despite anxiety or other uncomfortable internal experiences. Shifts focus from symptom elimination to life quality.

An SNRI antidepressant (Effexor) used for depression, anxiety, and chronic pain. At lower doses acts primarily on serotonin; at higher doses adds significant norepinephrine reuptake inhibition.

Extended-release SNRI with dose-dependent mechanism; at doses below 75 mg functions primarily as SSRI. Clinically significant noradrenergic effects emerge at 150+ mg/day. Severe discontinuation syndrome requires careful tapering.

Region providing primary inhibitory control over amygdala; smaller and less active in anxiety disorders. During extinction learning, vmPFC actively suppresses amygdala output. Strengthened by successful exposure therapy.

SSRI plus 5-HT1A partial agonist (dual mechanism) approved for MDD. Used off-label for anxiety disorders with theoretical advantage of faster anxiolytic onset via the partial agonist component. Take with food to ensure adequate absorption.

Exposure therapy conducted in immersive virtual environments (VR headsets) rather than in vivo or imagination-based, allowing controlled exposure to feared situations (flying, heights, social scenarios) with precise stimulus manipulation. Efficacy comparable to in vivo exposure; practical advantages include safety and accessibility.

Vesicular Monoamine Transporter 2. The protein that packages dopamine and norepinephrine into storage vesicles inside neurons.

Time required after discontinuing one medication before starting another, allowing the first drug to clear sufficiently to avoid interactions. Critical when switching between MAOIs and serotonergic agents (typically 14 days for MAOIs, 5 half-lives for the prior agent).

Weiss Functional Impairment Rating Scale. A validated measure of functional impairment across multiple domains.

World Federation of Societies of Biological Psychiatry. Publishes international evidence-based treatment guidelines for anxiety and related disorders, with systematic evidence grading (A through D) based on study quality.

The wiring that connects brain areas to each other. Disruptions in white matter integrity are associated with various psychiatric conditions.

World Health Organization Disability Assessment Schedule, Second Edition; 36-item (or 12-item short form) measure of functional disability across six domains including work, household, mobility, cognition, interpersonal, and participation. Transdiagnostic tool applicable across anxiety presentations.

The cognitive system that temporarily holds and manipulates information needed for complex tasks like reasoning, comprehension, and learning. A core executive function impaired in many individuals with ADHD. Depends on prefrontal cortex networks modulated by dopamine (D1 receptors) and norepinephrine (α2A receptors).

Borkovec's protocol for GAD where patient vividly imagines worst-case worry scenarios in sustained detail (blocking shift to abstract verbal processing) until anxiety naturally habituates. Addresses worry as avoidance mechanism.

Yale-Brown Obsessive Compulsive Scale; 10-item clinician-rated gold standard for OCD symptom severity measuring both obsessions and compulsions separately on severity scales. Total score 0-40; 16-23 mild, 24-31 moderate, 32-40 severe. Sensitive to treatment response.